Clinical Trial Update: Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on Phase I/II study of ipilimumab (MDX-010) in unresectable stage III or IV malignant melanoma, focusing on predictive markers of response…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• ipilimumab (ipilimumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Unresectable Stage III or IV Malignant Melanoma | Phase 1, Phase 2 | Status: COMPLETED